A team of Australian researchers has developed a new targeted therapeutic approach that could improve treatment for myelofibrosis -- a rare and serious form of blood cancer. 

Myelofibrosis disrupts the body’s ability to produce healthy blood cells, leading to fatigue, pain, enlarged spleen, and reduced quality of life.